Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03786380 · ClinicalTrials.gov registry record · Phase 3
Diabetic Gastroparesis Study 05
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT03786380 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 202 participants.
The verdict
NCT03786380, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 \[NCT03420781\] or RLM-MD-04 \[NCT03383146\] study and to provide treatment for these participants until relamorelin becomes commercially available or the Sponsor terminates development.
Interventions
- DRUG Relamorelin 10 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2020-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03786380
The ClinicalTrials.gov registry entry for NCT03786380 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Relamorelin 10 μg is the first listed.
NCT03786380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03786380 about?
NCT03786380 is a clinical study titled "Diabetic Gastroparesis Study 05". This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 \[NCT03420781\] or RLM-MD-04 \[NCT03383146\] study and to provide treatment for these participants until relamorelin becomes commercially available or the Spo...
What is the current status of trial NCT03786380?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2018-12-20. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT03786380?
The interventions under investigation include: Relamorelin 10 μg (DRUG).
Who is sponsoring clinical trial NCT03786380?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.